Compare · PRVA vs WGS
PRVA vs WGS
Side-by-side comparison of Privia Health Group Inc. (PRVA) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRVA and WGS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- PRVA is the larger of the two at $3.12B, about 1.7x WGS ($1.86B).
- Both names hit the wire about 5 times in the past 4 weeks.
- PRVA has more recent analyst coverage (25 ratings vs 8 for WGS).
- Company
- Privia Health Group Inc.
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $3.12B
- $1.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 8
Privia Health Group Inc.
Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.
Latest PRVA
- SEC Form 10-Q filed by Privia Health Group Inc.
- Privia Health Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results
- Privia Health Expands VBC Footprint with Acquisition of American Choice Healthcare MSSP Business
- SEC Form SCHEDULE 13G filed by Privia Health Group Inc.
- Privia Health to Report Third Quarter 2026 Results on Thursday, November 5
- Amendment: SEC Form SCHEDULE 13G/A filed by Privia Health Group Inc.
- Director Ernest Opella Finley was granted 6,350 shares (SEC Form 4)
- SEC Form 3 filed by new insider Ernest Opella Finley
- Privia Health Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest WGS
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)